In the heavily regulated life sciences space, proper data management and organization is key to an efficient drug development process. Technological advancements and innovations are positioned to streamline these complex efforts, but the next step is proper implementation. That’s why touching base with the industry for knowledge sharing is so important.
On February 11, 2019, members of the Daelight team will be in North Bethesda, Maryland to attend Drug Information Association’s (DIA) Regulatory Submissions, Information, and Document Management (RSIDM) Forum. The forum offers a comprehensive view of content and regulatory information management and submissions as they relate to drug development and product lifecycles.
“Our team is relentlessly focused on ensuring regulatory compliance for pharmaceutical, biotech and medical device firms,” said Daelight Founder and CEO Dan Wheeler. “We recognize the importance of connecting with the industry in order to bring best practice solutions to our clients. We’re looking forward to learning more about the space and ultimately taking away insights on how to even more effectively streamline information gathering, organization and submission activities.”
If you’re attending, feel free to contact us to set up time to talk about the latest in regulatory life sciences.